Interview with the CEO and Chairman of the Board of Glycomira Therapeutics, William P. Tew, PhD and CFO Kenneth R. North

The CEO and Chairman of the Board of GlycoMira Therapeutics, William P. Tew, is sharing interesting details about a promising small molecule immune modulator called GM-1111 that shows powerful anti-tumor activity with fewer side effects than traditional treatments. Originally designed as a safer anti-inflammatory, GM-1111 has evolved into a multimodal compound that not only targets the tumor microenvironment but also protects healthy tissue during treatment. In preclinical studies, it matched radiation in shrinking tumors and nearly eliminated them when used in combination.

Read the Bioneex Story with GlycoMira Therapeutics